-
Predicting Netarsudil–siRNA Nanoparticle Codelivery
2026-09-29
Slaughter and colleagues developed a quantitative workflow for predicting whether ionizable drugs can complex siRNA and support nanoparticle encapsulation. Netarsudil emerged as a high-performing candidate, enabling experimental codelivery of CTGF-targeting siRNA in fibrotic human trabecular meshwork cells and linking formulation descriptors with changes in gene expression and actin organization.
-
Allosteric Biosensor Tracks Native Protein Dynamics
2026-09-28
The study introduces circStep, an allosteric genetically encoded biosensor designed to visualize endogenous proteins in living cells without tagging or changing the target protein. By coupling protein recognition to activation of fluorogenic RNA aptamers, the approach aims to track protein abundance and relocalization in real time and support imaging-based drug screening.
-
Cabozantinib (XL184): Reliable Assay Design
2026-09-27
Practical guidance for interpreting viability, angiogenesis, and renal cell carcinoma experiments with Cabozantinib (XL184, BMS-907351). The article connects reported potency and exposure-dependent phosphoproteomic findings with handling considerations for SKU A2977.
-
Beyond FLT3 Mutation: A Translational Case for Quizartinib
2026-09-26
Quizartinib (AC220) offers a selective tool for testing FLT3 dependence in AML models. Emerging work in blast phase CML broadens the research question—from mutation status alone to FLT3-linked resistance biology—while underscoring the need to validate each model and inhibitor separately.
-
Cefiderocol Activity in Resistant European Enterobacterales
2026-09-26
A six-country European surveillance study found that cefiderocol remained active in vitro against most collected Enterobacterales, including many isolates resistant to meropenem and β-lactam/β-lactamase inhibitor combinations. Its large, direct comparison of approved and developmental agents also shows why resistance phenotype and genotype should be considered together when interpreting susceptibility results.
-
AMG 487: Reading CXCR3 Through Cell State
2026-09-25
A 2024 study places macrophage state and LAMP1 at the center of CXCL10–CXCR3 signaling, showing why CXCR3 blockade can produce opposite polarization outcomes in different inflammatory contexts. This article translates those findings into a state-aware experimental strategy using AMG 487.
-
Weight Loss Restores Gut Stretch-Induced Satiety
2026-09-25
This study shows that non-nutritive intestinal stretch can acutely reduce food intake and improve oral glucose tolerance, while diet-induced obesity weakens the feeding response. Both dietary and surgical weight loss restore stretch-induced satiety, highlighting intestinal mechanosensation as a metabolic signal distinct from nutrient and classical gut-hormone sensing.
-
Propranolol: Designing Exposure-Aware Assays
2026-09-24
Propranolol is a non-selective β-adrenergic receptor blocker whose experimental effects depend on both receptor biology and how exposure is controlled. This guide connects cardiovascular and neurobehavioral assay design with a careful pharmacogenomics lesson—without mistaking evidence about other drugs for evidence about propranolol.
-
3-Bromopyruvate Reverses Cetuximab Resistance in CRC
2026-09-24
A 2023 study found that combining 3-bromopyruvate with cetuximab suppressed colorectal cancer cells with intrinsic or acquired cetuximab resistance. The work links restored FOXO3a activity to coordinated ferroptosis, autophagy, and apoptosis, offering a mechanistic framework for investigating treatment resistance rather than evidence of clinical benefit.
-
Prostaglandin E2: Reliable Cell Assays
2026-09-23
Learn how Prostaglandin E2 (SKU B7005) can help scientists control receptor context, solvent effects, storage variables, and interpretation in cell viability, proliferation, and inflammation workflows. This scenario-based guide combines product specifications with practical assay design and recent inflammation-model evidence.
-
TMEM16F Lipid Scrambling in Ferroptosis and Immunity
2026-09-23
Yang et al. identify TMEM16F-mediated plasma-membrane lipid scrambling as an execution-stage suppressor of ferroptosis. Loss of TMEM16F intensifies membrane collapse, releases danger signals, slows tumor growth, and improves the response to PD-1 blockade, highlighting membrane biophysics as a determinant of tumor immunogenicity.
-
Honokiol at the Immunometabolic Translation Edge
2026-09-22
Honokiol offers translational researchers a way to interrogate the intersection of NF-κB signaling, oxidative stress, tumor biology, and CD8+ T-cell metabolic flexibility. By connecting the CD28-ARS2-PKM findings from recent immunology research with a rigorously controlled small-molecule workflow, this article outlines a hypothesis-driven path from pathway modulation to decision-quality cancer and inflammation studies.
-
Sabutoclax Workflow for Apoptosis Assays
2026-09-21
Sabutoclax is a pan-Bcl-2 inhibitor suited to mechanism-focused cancer assays that separate growth arrest from genuine cell killing. This workflow combines concentration-response profiling, apoptosis measurements, and model selection to improve interpretation across prostate, lung, and lymphoma systems.
-
CNQX: From Receptor Blockade to Circuit Insight
2026-09-21
CNQX connects precise AMPA/kainate receptor pharmacology with translational neurocardiology, helping researchers distinguish non-NMDA signaling from NMDA-dependent autonomic mechanisms while designing reproducible circuit-level experiments.
-
Amyloid Beta-Peptide (1-40): Assay Strategy
2026-09-20
Amyloid Beta-Peptide (1-40) (human) is a versatile reference substrate for connecting amyloid biophysics with fluorescence imaging and functional neuroscience. This guide explains how to design more discriminating Aβ40 assays using aggregation-state controls, ratiometric readouts, and careful peptide handling.